Mylan and Novartis to FDA: Where are the Suffixes?

Mylan and Novartis to FDA: Where are the Suffixes?

Source: 
RAPS.org
snippet: 

Mylan and Novartis are taking issue with the fact that the US Food and Drug Administration (FDA) has yet to begin issuing random suffixes for biologics’ names and so far has only used suffixes for biosimilars and a few recently approved biologics, according to comments released Wednesday.